Fig. 2: Kaplan-Meier analysis of time to progression (TTP) to secondary acute myeloid leukemia (AML) in 1225 patients with primary myelodysplastic neoplasm (MDS) in Asia.

A Time to progression to secondary AML in primary MDS in Asia; B Adverse prognostic impact of isochromosome 17q [i(17q)] on time to progression to secondary AML in primary MDS in Asia; C Adverse prognostic impact of 5q deletion [del(5q)] on time to progression to secondary AML in primary MDS in Asia; D Adverse prognostic impact of NPM1 mutations on time to progression to secondary AML in primary MDS in Asia; E Adverse prognostic impact of NRAS mutations on time to progression to secondary AML in primary MDS in Asia; F Adverse prognostic impact of GNAS mutations on time to progression to secondary AML in primary MDS in Asia; G Adverse prognostic impact of IDH2 mutations on time to progression to secondary AML in primary MDS in Asia; H Adverse prognostic impact of SF3B1 mutations on time to progression to secondary AML in primary MDS in Asia; I Adverse prognostic impact of RUNX1 mutations on time to progression to secondary AML in primary MDS in Asia. All P values were obtained using log-rank test. The genomic factors shown were significant on multivariable analysis (see Table 2).